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Aims: Calcitonin gene-related peptide (CGRP) is a potent vasodilator neuropeptide. We investigated the
ameliorating effect of CGRP in myocardial ischemia induced by endothelin-1 (ET-1), with special emphasis
on myocardial microvascular hemodynamics and levels of energy-related metabolites.
Main methods: The Langendorff preparations of rat isolated heart were perfused at a constant ﬂow rate.
Microvascular blood ﬂow was also visualized in the anterior epicardium of the left ventricle by means of
an intravital ﬂuorescence microscope system. Energy-related metabolite contents in the myocardium
were measured by means of 31P-magnetic resonance spectroscopy (31P-MRS).
Key ﬁndings: Intracoronary bolus injections of CGRP caused dose-dependent decreases in coronary perfusion
pressure (CPP) in the hearts exposed to ET-1 (30 pmol). The vasodilator potency of CGRP was about 10,000-
fold greater than that of nitroglycerin and 1,000-fold greater than that of isobutylmethylxanthine. Vasodilation
of the small-sized arterioles (10–40 μm in diameter) in response to CGRP (100 pmol) was conﬁrmed by direct
microscopic observation. After ET-1 (30 pmol) plus vehicle administration, high energy phosphates (phospho-
creatine (PCr), ATP) were markedly reduced (p b 0.05). CGRP administration signiﬁcantly (p b 0.05) attenuated
the anaerobic changes in the myocardium (decrease in PCr) and macrohemodynamic alterations (increase in
CPP, decrease in dP/dt etc.) induced by ET-1.
Signiﬁcance: We conclude that CGRP effectively confers hemodynamic and metabolic protections to isolated
beating hearts against ET-1-induced myocardial ischemia.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Cumulative intracoronary application of the potent vasoconstrictor
peptide endothelin-1 (ET-1), discovered by Yanagisawa et al. (1988),
has been reported to reduce coronary blood ﬂow even in the absence
of detectable vasospasm of large epicardial arteries (Kurihara et al.,
1989; Larkin et al., 1989; Kolettis et al., 2013). This observation indicates
that small resistance vessels are more sensitive to ET-1 than large
conduit arteries in the heart (Miyauchi and Goto, 2013). Using intravital
microscopy, we previously found that intracoronary administration of
ET-1 in the Langendorff perfusion preparation elicited more prominent
vasoconstriction of the small-sized arterioles than the large onesonal Conference on Endothelin
ber 8–11, 2013), and was pub-
-64: 2013) of this Meeting.
81 29 853 3143.
a).
. This is an open access article under(Homma et al., 1992). In view of these ﬁndings, among previously
reported vasoactive agents, ET-1 is believed to be the most potent
microvascular constrictor of the small-sized microvessels (Tang and
Vanhoutte, 2010; Kolettis et al., 2013; Miyauchi and Goto, 2013). The
endothelin (ET) system consists of two G protein coupled-receptors,
namely ETA and ETB receptors, and three endogenous ligands, ET-1,
ET-2, and ET-3 (Horinouchi et al., 2013).
Although the vasoactive properties of ET-1 are widely recognized,
minimal attention has been given to potential intrinsic physiological
antagonistic mechanisms which may limit the vasoconstrictor's ef-
fects. Accumulation of recent knowledge in vascular pharmacology
has revealed that several endogenously formed vasoactive agents,
such as prostacyclin, vasoactive intestinal peptide (VIP), atrial natri-
uretic polypeptide (ANP) and the endothelium-dependent relaxing
factor (EDRF) nitric oxide (NO), might control vascular smooth
muscle tonus and act as vasodilators (Brayden and Bevan, 1985;
Furchgott and Vanhoutte, 1989). However, to date there have beenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ical antagonists of ET-1. Compared with these vasodilator agents,
calcitonin gene-related peptide (CGRP) is of particular interest as a
possible physiological antagonist of ET-1 (Homma et al., 1991a) be-
cause of the following facts: 1) it is an extremely potent vasodilator
of isolated coronary arteries (McEwan et al., 1986; Greenberg et al.,
1987; Shoji et al., 1987); 2) perivascular plexuses of CGRP-like
immunoreactive ﬁbers are widely distributed in the cardiovascular
system (Mulderry et al., 1985; Wharton et al., 1986); 3) like ET-1,
CGRP exerts slow stable effects on the heart (Goto et al., 1987); and
4) myocardial ischemia enhances local intravascular CGRP release
from peri-coronary arterial nerves (Franco-Cereceda et al., 1989;
Mair et al., 1990). Although itwas reported that CGRP acts as a physiolog-
ical antagonist of the vascular effects of ET-1 in the systemic circulation in
the rat (Meens et al., 2009, 2010, 2011, 2012; DeMey et al., 2011) and in
large and small human coronary arteries (Labruijere et al., 2013), the
antagonistic action of CGRP to the vasoconstrictive effect of ET-1 at
the microcirculation level in the heart has never been studied.
Based on our ﬁndings that ET-1 induces pronounced changes in the
luminal diameter of heart microvasculature (Homma et al., 1991b,
1992), we suggested at the time that most likely metabolic alterations
were important determinants of the hemodynamicmicrocirculation re-
sponses to ET-1 administration. Thus, in the current study we investi-
gate the pharmacological interactions between CGRP and ET-1, with
respect to their inﬂuences on myocardial hemodynamic and metabolic
functions. The results presented herein show, for the ﬁrst time, that
CGRP potently alleviates the vasoconstrictor and metabolic effects of
ET-1 in the heart.
Materials and methods
Animal preparation to investigate the effect of CGRP and ET-1
Male Wistar rats (n = 17) weighing 250–350 g were anesthetized
with an i.p. injection of pentobarbital sodium (50 mg/kg), injected
with sodium heparin (200 units/kg) into the jugular vein, for the pur-
pose of anticoagulation, and the heart was removed and immediately
immersed in ice-cold Krebs–Ringer solution. The Langendorff perfusion
preparation was made by inserting a polyethylene catheter into the
aorta, in order to retrogradely perfuse the heartwithKrebs–Ringer solu-
tion aerated with 95% and 5% CO2 mixture at 37 °C by means of a roller
pump at a constant ﬂow rate of 3.0 ml/min, as described previously
(Homma et al., 1991b, 1992). Heart arrest was promptly reverted once
perfusion with warm oxygenated perfusate was initiated. Composition
of the Krebs–Ringer solution was (in mM): NaCl 113, KCI 4.8, CaCl2
2.2, MgSO4, 1.2, NaHCO3 25, KH2PO4 5.5 and Glucose 5.5. After an equil-
ibration period of 15 min, a bolus injection of ET-1 (30 pmol; Peptide
Institute, Osaka, Japan) was given to increase perfusion pressure. Once
the response to ET-1 plateaued (usually in about 7 min after injection),
boluses of other vasoactive agents were injected cumulatively into the
perfusate, in increasing doses, through a catheter placed in the perfu-
sion circuit. These vasoactive agents and respective doses used were:
CGRP (human CGRP, 1–1000 pmol; Peptide Institute, Osaka, Japan),
followed either by nitroglycerine (NTG; 10–3000 nmol; Nippon
Kayaku Co., Tokyo, Japan) or isobutylmethylxanthine (IBMX;
10 pmol–3000 nmol; Wako Pure Chemicals Industries Ltd., Osaka,
Japan). The changes in perfusion pressure accompanying administration
of CGRP, NTG or IBMX were measured as previously described (Homma
et al., 1992). In other experiments, after examining the effects of CGRP
(100 pmol) on the ET-1-enhanced coronary perfusion pressure in the
Langendorff circuit, its accompanying effects on microcirculatory blood
ﬂow in the myocardium were visualized under an intravital microscope
system, to enable measurement of changes in microvessel diameter.
The intravital television microscope system used in such experiments
was previously described in detail elsewhere (Ohshima and Sato, 1987)
(Sato and Ohshima, 1990). In short, the heart was placed on a speciallydesigned holder to prevent lateral sliding motions. To attain clear vi-
sualization of the microvessels, FITC-labeled dextran was dissolved
in the perfusate, and its ﬂuorescence was visualized through a CCD
video camera under an epi-illuminated ﬂuorescencemicroscope sys-
tem. A ﬁnal magniﬁcation of 500–2000 was attained on a monitor TV
screen by use of a plain or water-immersion objective lens, which
was focused on the microvessels at the late diastolic phase of the
cardiac cycles. Blood ﬂow observation was made in the anterior epi-
cardium of the left ventricle, in particular, at the site of the bifurca-
tion of arterioles (10–40 μm in diameter). The dose of ET-1 chosen
(30 pmol) for use in this study is maximally effective in promoting
vasoconstriction of arterioles in the rat myocardium (Homma et al.,
1991a), whereas the dose of CGRP (100 pmol) was selected because
it corresponds roughly to the ED50 value for decreasing perfusion
pressure in the preparation.
Myocardial metabolism
To evaluate metabolic state of the myocardium accompanying ET-1
administration, intramuscular pH was ﬁrst measured by directly
inserting amicro-pH sensor (model PH-2135, Kuraray Co., Ltd., Okayama,
Japan) into the myocardium of the anterior wall of the left ventricle. The
Langendorff preparations of rat heart (n=5)were set up and given ET-1
(30 pmol) as described before, and the changes in intramuscular
pH were monitored for 60 min. In a separate series of experiments
(n = 20), both myocardial contractility and metabolic state of the
myocardium were examined simultaneously. To measure the left
ventricular pressure (LVP) in such preparations, a latex balloon was
introduced into the left ventricle (LV) though the left atrium and this
parameter were monitored throughout the experiment alongside its
ﬁrst derivative (dP/dt), coronary perfusion pressure (CPP) and heart
rate (HR). Each preparation was mounted inside the magnetic coil of a
31P-MRS apparatus (GX-400, JEOL, Tokyo, Japan) and carefully main-
tained at 37 °C. Preliminary experiments conﬁrmed that phosphocrea-
tine (PCr) content in the myocardium attained a stable value 15 min
after initiating perfusion. After the 15min-stabilization period, baseline
measurements of high energy-phosphates content (PCr and ATP) and
pH in the myocardium were carried out for 12 min. After the baseline
measurements, the ET-1 (30 pmol) with vehicle (0.02% albumin solu-
tion in PBS) or the ET-1 with CGRP (100 pmol) were injected into the
perfusate, and the high-energy phosphate contents and pH were con-
tinuously monitored for 30 min. An MRS was averaged from data of
45 spectra acquired under conditions of a pulse width of 85 μs and a re-
cycle time of 4 s.
Statistical analysis
In all experiments statistical differences of % change from the control
state between two groups were analyzed using analysis of variance
(ANOVA) followed by an unpaired t-test (Wallenstein et al., 1980). Dif-
ferenceswith values of p less than 0.05were considered statistically sig-
niﬁcant in all tests. All experimental data are presented asmean± SEM.
Results
Dose–response curves to ET-1, CGRP, NTG and IBMX
Curves for the depressor effects of CGRP (n = 7), NTG (n = 5) and
IBMX (n = 5) following perfusion with 30 pmol ET-1 were obtained
from a total of 17 Langendorff heart preparations. Fig. 1 illustrates typical
time course tracings of the CPP responses to ET-1 alone and upon injec-
tions of CGRP or NTG to preparations pre-exposed to ET-1 (30 pmol). It
should be noted that ET-1 caused an elevation in CPP which was stable
for more than 30 min after injection (Fig. 1a), and that after precontrac-
tion with ET-1 cumulative application of increasing bolus doses of CGRP
(3–1000 pmol; Fig. 1b) or NTG (10–1000 nmol; Fig. 1c) each induced
Fig. 1. Response of perfusion pressure to the administration of (a) ET-1, (b) CGRP
(3–1000 pmol), and (c) NTG (10–1000 nmol) after the precontraction with ET-1
(30 pmol). Note that the doses of CGRP used in this experiment were approximately
three orders of magnitude smaller than that of NTG. Fig. 3. CGRP induces vasorelaxation of a coronary arteriole precontracted with ET-1. A se-
ries of photomicrographs shows consecutive images of arterioles taken during a control
(resting) state (A), after ET-1 injection (B) and after subsequent CGRP injection (C). In
each image, the direction of ﬂow was from right to left, and the bar shown at the bottom
of (C) indicates 50 μm. The lower trace shows the time course of perfusion pressure chang-
es and indicates the time points at which each of the images was obtained.
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tive at far lower doses than NTG, addition of the highest dose of NTG
(1000 nmol) after completing the CGRP curve caused an additional re-
duction in CPP to a level similar to that recorded prior to ET-1 injection.
The mean dose–response curves for the depressor effects of CGRP, NTG
and the phosphodiesterase inhibitor IBMX on CPP are depicted in Fig. 2.
Although the ED50 value of CGRP (2.82 × 10−11 mol) was about four or-
ders of magnitude smaller than that of NTG (2.19 × 10−7 mol) and three
orders of magnitude smaller than that of IBMX (1.74 × 10−8 mol), the
maximal decrease in CPP induced by CGRP was smaller than that pro-
duced by NTG or IBMX.Microvascular responses
Intravital microscopic observation of myocardial microcirculation
also revealed prominent effects of ET and CGRP. Fig. 3 presents a series
of photomicrographs showing typicalmicroscopic images of an arteriole
under control conditions (Fig. 3A) and after consecutive injections of
ET-1 (Fig. 3B) and CGRP (Fig. 3C). The actual CPP values recorded at
the speciﬁc time points when each image was obtained by an arrow
head are indicated in the time course tracing of the CPP response to
CGRP. It is evident that ET-1 caused a marked and diffuse vasoconstric-
tion of the arteriole, allied to a localized vasospasm (near the bifurcation
indicated by an arrow in Fig. 3B). Subsequent injection of CGRP promot-
ed vasodilation over the entire length of the arteriole, except at the
point of vasospasm. Similar ﬁndings were observed in cardiac arteriolesFig. 2. Dose–response curve for the vasodilator effects of CGRP, NTG and IBMX.preconstricted with ET-1 of another 6 preparations, yielding a mean
relaxant effect of CGRP of 47.1 ± 5.4%.
Changes in heart rate and myocardial contractility
The tracings depicted in Fig. 4 illustrate the typical changes in hemo-
dynamic parameters recorded in the Langendorff preparations following
injection of ET-1 alone (Fig. 4a) or together with CGRP (Fig. 4b). It can be
seen that ET-1 alone promoted a sustained increase in CPP and transient
increases in LVP and dP/dT followed by a more prolonged decrease in
bothparameters, accompanied by an early small and short-liveddecrease
in HR. In comparison, when ET-1 was injected concomitantly with CGRP,
the resulting increase in CPP wasmuch smaller, but the increases in both
LVD anddP/dTwere clearly sustainedwith no evident signs of depression
at later stages, and HR was modestly and persistently increased.
Themean results of some of these experiments (CPP, HR and dP/dT),
recorded over the ﬁrst 30 min after the injections, are shown in Fig. 5. It
should be noted that the magnitude of CPP changes induced by each of
the injections was signiﬁcantly different over the full length of the ob-
servation period, whereas the differences in HR and dP/dT only
achieved statistical signiﬁcance at few time points. On the other hand,
the CGRP injection together with ET-1 clearly induced the increase of
the products of dP/dt and HR (i.e. cardiac work index) compared to
only the ET-1 application (Fig. 5d).
Metabolic changes induced in the myocardium
Fig. 6 shows a typical tracing of the decrease in myocardium pH, as
recorded by use of a micro pH sensor, following the injection of ET-1
(30 pmol). As it was possible that this ﬁnding could reﬂect a state of se-
vere metabolic acidosis, due to the vasoconstriction produced by ET-1
and consequent poormyocardial perfusion,we used 31P-magnetic reso-
nance spectrum (SIP-MRS) analysis to examine in more detail the
metabolic changes of isolated and perfused hearts induced by injection
of ET-1 alone or plus CGRP. Typical tracings of theNMR spectra obtained
at various time points prior to and following each of the two types of
injection are illustrated in Fig. 7, whereas the mean results obtained
by integrating the peaks of the 31P-MRS spectra of seven hearts per
Fig. 4. Typical examples ofmacrohemodynamic parameters. CPP, LVP, dP/dt andHR for the runs administered ET-1with vehicle (a), and a concurrent injection of ET-1with CGRP (b). CPP,
coronary perfusion pressure; LVP, left ventricle pressure; dP/dt, ﬁrst derivative of left ventricle pressure; HR, heart rate.
Fig. 5. Time course changes in perfusion pressure (a), heart rate (b), dP/dt (c), and work index (d) before and after the injection of ET-1 with vehicle (●) or the concurrent injection of ET-1 with
CGRP (○). ET-1, 30 pmol; CGRP, 100 pmol; vehicle, 100 µl of 0.02% albumin in Krebs–Ringer solution. Difference between the ET-1with vehicle and the concurrent injection of ET-1with CGRP.
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Fig. 6. Typical tracing of the change inmyocardium pHmeasured by direct insertion of pH
sensor after 30 pmol of ET-1 administration.
252 S. Homma et al. / Life Sciences 118 (2014) 248–254group are depicted in Fig. 8. The concurrent administration of CGRP to-
gether with ET-1 resulted in the signiﬁcant increase in PCr compared to
only the ET-1 administration (Fig. 8A). Myocardial pH was also calculat-
ed from the difference in the chemical shifts of the PCr and Pi peaks in the
31P-MRS spectrum, and the values found correlated well with the mea-
surement of intramuscular pH using the micro pH sensor (Figs. 6 and
8D). On the other hand, ATP, Pi, and pH failed to achieve statistical signif-
icance between the ET-1with vehicle and the concurrent injection of ET-
1 with CGRP.
Discussion
The present investigation revealed that CGRP exerts potent cardiac
microvascular vasodilator effects and can act as an intrinsic physiologi-
cal antagonist of ET-1 in the rat isolated perfused heart. Moreover, it has
characterized several features of myocardial ischemia induced by ET-1,
including alterations in cardiac metabolic state. Finally, it also demon-
strated that exogenous CGRP protects the heart from the microcircula-
tory and myocardial metabolic disturbances promoted by ET-1.
CGRP has been shown to display potent vasodilator actions in large
isolated blood vessels, such as rat aorta, porcine coronary arteries, and
human skeletal muscle arteries (Brain et al., 1985; Shoji et al., 1987;
Pernow, 1989), as well as small arteries, resistance vessels and
microvessels in various perfused organs and tissues including human
skin and rabbit skeletal muscle microcirculation and mesenteric
microvessels (Brain et al., 1985; Ohlén et al., 1987; Kawasaki et al.,
1988). It was reported that CGRP acts as a physiological antagonist of
the vascular effects of ET-1 in the systemic circulation in the rat
(Meens et al., 2009, 2010, 2011, 2012; De Mey et al., 2011). However,
there are very few reports on the actions of CGRP in the coronaryFig. 7. Typical tracing of 31P-MRS and their time course changes, superimposed in the Z axis, obt
(a), and ET-1 with CGRP (b). Phosphocreatine, PCr; inorganic phosphate, Pi.circulation (Holman et al., 1986; McEwan et al., 1986; Ludman et al.,
1991), and virtually no direct demonstrations by intravital microscopy
of the effect of CGRP on coronary microcirculation. In this regard, the
current study reveals, for theﬁrst time, that CGRP is a remarkably potent
microvascular vasodilator in the myocardium, capable of dose-
dependently reversing the elevation of CPP and arteriolar constrictions
induced by ET-1 in isolated heart Langendorff preparations. It is also in-
teresting to note that the ED50 values for the CPP enhancing effect of ET-
1 (Homma et al., 1992) and the CPP depressor effect of CGRP (present
study) in the rat isolated and perfused heart are quite similar, indicating
that its potency in promoting vasodilation of the coronary vasculature is
comparable to that of ET-1 inducing vasoconstriction.
Several studies have shown that ET-1 exerts positive inotropic actions
in freshly isolated and culturedmyocardial cells or in isolated cardiac atri-
al or ventricular preparations (Moravec et al., 1989; Shah et al., 1989;
Kelly et al., 1990; Kaoukis et al., 2013;Miyauchi andGoto, 2013). Interest-
ingly and inmarked contrast, we observed herein that ET-1 application to
rat isolated perfused spontaneously beating hearts promoted a transient
increase in LVP which was rapidly replaced by a long-lasting negative
inotropic effect. One of the potential reasons which might account for
the distinct inotropic effects of ET-1 is that it may promptly and severely
exhaust themyocardial energy stores utilized to sustain contractile func-
tion in the Langendorff preparation. In an earlier study in the same prep-
aration (Homma et al., 1992), we showed that ET-1 potently constricted
small sized arterioles and at higher doses completely blocked capillary
blood ﬂow in the myocardium. Mechanistically, a plausible hypothesis
is that the reduced coronary perfusion on exposure to ET-1 could block
the aerobic metabolic pathway in the local myocardium, thus accelerat-
ing anaerobic metabolism and decreasing myocardial contractility.
Indeed, this view is substantiated by the results we obtained in the
myocardial metabolism analysis experiments using 31P-MRS. This
method enables real-time in situ detection of the free high energy phos-
phate contents in the isolated beating heart (Argov et al., 1987;
Aussedat et al., 1991). Moreover, PCr, ATP and Pi contents detected by
this method quantitatively reﬂect the aerobic conditions of the speci-
men (Aussedat et al., 1991), and correlate well with the values obtained
using classical biochemicalmethods of analysis (Humphrey andGarlick,
1991). When compared to the effects promoted by ET-1 alone, the
concomitant administration of CGRP (together with ET-1) clearly
counteracted the long-lasting negative inotropic effect, increased cardi-
acwork index and lessened the decrease of high energy phosphate con-
tent of the whole heart. These actions of CGRPmight be partly due to its
enhancing effects on capillary blood ﬂow, and partly because the
peptide exerts a direct positive inotropic action of its own in isolated
myocardial muscle (Ishikawa et al., 1988a, 1988b). Thus, our results
suggest that: 1) impairment of cardiac contractility by ET-1 is due toained from an isolated perfused rat heart before and after the injection of ET-1with vehicle
Fig. 8. Time course changes in PCr (a), ATP (b), Pi (c), and pH (d) before and after the injection of ET-1with vehicle (●) or the concurrent injection of ET-1with CGRP (○). ET-1, 30 pmol;
CGRP, 100 pmol; vehicle, 100 µl of 0.02% albumin in Krebs–Ringer solution. Phosphocreatine, PCr; inorganic phosphate, Pi. Difference between the ET-1 with vehicle and the concurrent
injection of ET-1 with CGRP. We determined 0% (baseline) by the calculation of the mean of the 5 points from the time minus 12 min to time zero.
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insufﬁcient local myocardial perfusion; and 2), in part by its relaxant
effect on the coronary microvasculature, CGRP can counteract these ac-
tions of ET-1 to dramatically improve myocardial metabolic conditions
and performance.
Coronary blood ﬂow is believed to be ﬁnely tuned, by a precise con-
trol mechanism, to meet the metabolic demand of the myocardium,
thus affording strong protection against ischemic insults (Berne,
1980). Since, in the present study, the preparations were perfused at a
ﬁxed ﬂow rate, it is likely that ET-1 might redistribute perfusate ﬂow
in the coronary microcirculation to affect cardiac metabolism or con-
tractile function heterogeneously, and this action is modulated by
CGRP. In other words, signiﬁcant metabolic and functional alterations
may occur well in restricted loci of the myocardium even in conditions
when the volumetric ﬂow rate supplied to the large coronary arteries is
unchanged. Few studies have described the effects of other vasoactive
agents on metabolic conditions of the heart, all of them conducted in
dogs. In this regard, net myocardial lactate production was unchanged
by adrenergic vasoconstriction even in when coronary artery stenosis
was present (Bufﬁngton and Feigl, 1981). Likewise, no change in ar-
teriovenous lactate extraction was detected following intracardiac
vasopressin administration (Corliss et al., 1968; Wilson et al., 1980).
Moreover, doses of vasopressin sufﬁcient to decrease coronary blood
ﬂow and myocardial contractile force caused no essential change in the
myocardial contractile force when the coronary arterial blood ﬂow was
kept constant with a roller pump (Nakano, 1967), and intracoronary in-
fusion of vasopressin elicited only a slight decrease in subendocardial pH
from 7.40 to 7.31 (Maturi et al., 1991). Clearly, ET-1 was found to pro-
mote amuch largermetabolic change in perfused rat heart in the current
study than those reported for vasopressin and adrenergic stimula-
tion in dog heart. The interstitial acidosis observed following ET-1administration might be particularly relevant with respect to ET-1/
CGRP crosstalk. Low pH is a potent stimulus for the release of CGRP
by peri-vascular sensorimotor nerves (Fanciullacci et al., 1991) and
these nerves in turn express ET-receptors (Wang and Wang, 2004;
Meens et al., 2009). However, it remains to be determined if the
marked difference between the metabolic effects of these vasoactive
substances and ET-1 reﬂects merely the interspecies variation or
truly stems from their distinct mechanisms of action.
In conclusion, the present study has shown that, in the perfused rat
heart, ET-1 enhances anaerobic metabolism in the myocardium, most
likely via a marked reduction in coronary perfusion, and that these
effects are potently alleviated by CGRP. These results strongly suggest
that CGRP may act as an intrinsic physiological antagonist of ET-1 to
control not only vasomotor tone in the coronary microcirculation, but
also themetabolic condition of themyocardium. CGRP has been reported
to exert its actions by binding to speciﬁc CGRP receptors coupled to cAMP
(Shoji et al., 1987). However, several lines of evidence point to a closer re-
lationship between CGRP and ET-1, whereby CGRP could counteract the
effects of ET-1 by acting as an allosteric antagonist of endothelin ETA re-
ceptors (De Mey et al., 2011). Further investigations are thus needed to
elucidate in greater detail the mechanisms underlying the interactions
between ET-1 and CGRP seen in the rat isolated perfused heart.
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